Lexaria Bioscience Corp. Common Stock (LEXX) Stock Price

LEXXStock

$2.86−76.90%52W

Market Cap$6.02M

P/E—

PEG Ratio—

Div yield—

Beta0.64

LEXX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-91.21%

Price vs S&P 500 (4W)-15.17%

VGM Score26.28

Book Value / Share (Quarterly)$2.87

P/TBV (Annual)6.42x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)39.51%

Cash Flow / Share (Quarterly)$-4.64

Price vs S&P 500 (YTD)-81.01%

Gross Margin (TTM)100.00%

Net Profit Margin (TTM)-2156.23%

EPS (TTM)$-3.35

10-Day Avg Trading Volume0.09M

EPS Excl Extra (TTM)$-3.35

Revenue Growth (5Y)17.89%

EPS (Annual)$-9.92

ROI (Annual)-398.09%

Gross Margin (Annual)99.61%

Net Profit Margin (5Y Avg)-1837.15%

Cash / Share (Quarterly)$2.19

Revenue Growth QoQ (YoY)-88.51%

ROA (Last FY)-285.07%

Revenue Growth TTM (YoY)-68.50%

EBITD / Share (TTM)$-1.26

ROE (5Y Avg)-162.22%

Operating Margin (TTM)-2157.06%

Cash Flow / Share (Annual)$-8.20

P/B Ratio1.27x

P/B Ratio (Quarterly)3.22x

Net Income / Employee (Annual)$-1,700,300

EV / Revenue (TTM)6.93x

ROA (TTM)-143.89%

EV / EBITDA (TTM)122.04x

EPS Incl Extra (Annual)$-9.92

Current Ratio (Annual)2.32x

Quick Ratio (Quarterly)9.56x

3-Month Avg Trading Volume0.05M

52-Week Price Return-76.90%

Revenue / Employee (TTM)$27,700

Tangible BV / Share (Quarterly)$2.66

P/S Ratio (Annual)8.53x

Asset Turnover (Annual)0.17x

52-Week High$21.60

Operating Margin (5Y Avg)-1896.92%

EPS Excl Extra (Annual)$-9.92

CapEx CAGR (5Y)51.95%

Tangible BV CAGR (5Y)3.67%

26-Week Price Return-81.31%

Quick Ratio (Annual)1.56x

13-Week Price Return-70.02%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)10.60x

Enterprise Value$2.55M

Revenue / Share Growth (5Y)39.37%

Asset Turnover (TTM)0.06x

Book Value / Share Growth (5Y)22.14%

Revenue / Employee (Annual)$100,800

Inventory Turnover (Annual)1.50x

Pretax Margin (Annual)-1687.36%

Cash / Share (Annual)$1.51

3-Month Return Std Dev184.92%

Gross Margin (5Y Avg)85.36%

Net Income / Employee (TTM)$-1,104,600

ROE (Last FY)-398.09%

EPS Basic Excl Extra (Annual)$-9.92

P/FCF (TTM)26.19x

Receivables Turnover (TTM)4.54x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-3.35

Receivables Turnover (Annual)4.54x

ROI (TTM)-160.72%

P/S Ratio (TTM)16.37x

Pretax Margin (5Y Avg)-1896.92%

Revenue / Share (Annual)$0.59

Tangible BV / Share (Annual)$2.06

Price vs S&P 500 (52W)-92.43%

Year-to-Date Return-69.08%

5-Day Price Return-12.54%

EPS Normalized (Annual)$-9.92

ROA (5Y Avg)-137.97%

Net Profit Margin (Annual)-1686.00%

Month-to-Date Return-9.21%

Cash Flow / Share (TTM)$-1.13

EBITD / Share (Annual)$-9.85

Operating Margin (Annual)-1687.36%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-162.22%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-3.35

P/TBV (Quarterly)3.47x

P/B Ratio (Annual)5.76x

Inventory Turnover (TTM)1.50x

Pretax Margin (TTM)-2157.06%

Book Value / Share (Annual)$2.29

Price vs S&P 500 (13W)-72.71%

Beta0.64x

P/FCF (Annual)26.19x

Revenue / Share (TTM)$0.12

ROE (TTM)-160.72%

52-Week Low$2.43

vGradeD

gGradeD

mGradeF

vgmGradeD

LEXX Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Jul 13, 2026	-$0.90	-$1.20	-33.33%(-$0.30)
Q1 2026	Apr 13, 2026	-$1.05	-$0.90	+14.29%(+$0.15)
Q4 2025	Jan 13, 2026	-$1.95	-$1.05	+46.15%(+$0.90)
Q3 2025	Nov 27, 2025	-$2.35	-$1.95	+17.02%(+$0.40)

LEXX Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.14

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
LEXXLexaria Bioscience Corp. Common Stock	D	D	F	16.4x	-68.5%	100.0%	—	$2.86
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Lexaria Bioscience Corp. Common Stock

Lexaria Bioscience is a biotechnology company that generates revenue by licensing its proprietary DehydraTECH drug delivery technology, which enhances the bioavailability and effectiveness of active pharmaceutical ingredients. The platform has broad applicability across therapeutics including GLP-1 drugs, pain medications, cannabinoids, and more, serving disease areas like diabetes, weight loss, and hypertension. DehydraTECH can be incorporated into multiple product formats—tablets, capsules, beverages, and foods—for use in pharmaceuticals, nutraceuticals, and consumer products.